IL-17E/IL-25 Antibody (IL25/625) [Janelia Fluor® 585]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-14176JF585
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Applications
Immunohistochemistry-Paraffin
Label
Janelia Fluor 585
Antibody Source
Monoclonal Mouse IgG1 kappa Clone # IL25/625
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Summary for IL-17E/IL-25 Antibody (IL25/625) [Janelia Fluor® 585]
Immunogen
Recombinant fragment of human IL-17E/IL-25 protein (exact sequence is proprietary) (Uniprot: IDQ9H293)
Localization
Secreted
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1 kappa
Applications for IL-17E/IL-25 Antibody (IL25/625) [Janelia Fluor® 585]
Application
Recommended Usage
Immunohistochemistry-Paraffin
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: IL-17E/IL-25
Long Name
Interleukin 17E
Alternate Names
IL-25, IL17E, IL25
Gene Symbol
IL25
Additional IL-17E/IL-25 Products
Product Documents for IL-17E/IL-25 Antibody (IL25/625) [Janelia Fluor® 585]
Product Specific Notices for IL-17E/IL-25 Antibody (IL25/625) [Janelia Fluor® 585]
Sold under license from the Howard Hughes Medical Institute, Janelia Research Campus.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...